US regulators have given tentative approval to a generic version of lenacapavir, a long-acting HIV prevention injection that will cost $40 per person annually in 120 low- and middle-income countries. This development is seen as potentially crucial for regions like Africa where funding cuts have impacted HIV-prevention programs. The approval aims to make the drug more accessible and could significantly contribute to…
FDA grants tentative approval to low-cost HIV shot (this article)
